Astrana Health, Inc. (NASDAQ:ASTH) Short Interest Up 5.1% in November

Astrana Health, Inc. (NASDAQ:ASTH) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 1,640,000 shares, a growth of 5.1% from the November 15th total of 1,560,000 shares. Based on an average daily volume of 299,300 shares, the short-interest ratio is presently 5.5 days. Approximately 4.6% of the company’s stock are short sold.

Institutional Trading of Astrana Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new position in shares of Astrana Health in the 3rd quarter valued at $1,164,000. Royce & Associates LP acquired a new position in Astrana Health in the third quarter valued at $6,661,000. Amalgamated Bank purchased a new position in shares of Astrana Health during the third quarter worth about $713,000. Principal Financial Group Inc. acquired a new stake in shares of Astrana Health during the third quarter worth about $13,383,000. Finally, Diamond Hill Capital Management Inc. purchased a new stake in shares of Astrana Health in the 3rd quarter valued at about $8,245,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Stock Performance

NASDAQ:ASTH opened at $35.52 on Wednesday. The firm has a market capitalization of $2.00 billion, a PE ratio of 27.38, a price-to-earnings-growth ratio of 1.80 and a beta of 1.13. The business’s fifty day moving average price is $49.04 and its 200 day moving average price is $48.12. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. Astrana Health has a 12 month low of $34.11 and a 12 month high of $63.20.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The business had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same quarter in the prior year, the business posted $0.47 EPS. On average, sell-side analysts anticipate that Astrana Health will post 1.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ASTH shares. KeyCorp assumed coverage on shares of Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. BTIG Research increased their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. Robert W. Baird boosted their target price on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, TD Cowen started coverage on Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $65.17.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.